| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPP1R14A |
| Uniprot No | Q96A00 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MAAQRLGKRV LSKLQSPSRA RGPGGSPGGL QKRHARVTVK YDRRELQRRL DVEKWIDGRL EELYRGMEAD MPDEINIDEL LELESEEERS RKIQGLLKSC GKPVEDFIQE LLAKLQGLHR QPGLRQPSPS HDGSLSPLQD RARTAHP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PPP1R14A重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**：*"Recombinant CPI-17 regulates myosin phosphatase activity in smooth muscle"*
**作者**：Eto M, et al.
**摘要**：研究报道了重组表达的PPP1R14A(CPI-17)蛋白通过抑制肌球蛋白磷酸酶活性调控平滑肌收缩的分子机制，揭示了其在钙敏感性信号通路中的作用。
2. **文献名称**：*"Characterization of recombinant human CPI-17 as a specific inhibitor of protein phosphatase 1"*
**作者**：Hirano K, et al.
**摘要**：通过重组表达人源PPP1R14A蛋白，验证其作为蛋白磷酸酶1(PP1)特异性抑制剂的活性，并探讨其在血管收缩和高血压病理中的潜在应用。
3. **文献名称**：*"Phosphorylation-dependent conformational switching of CPI-17 regulates PP1 inhibition in smooth muscle"*
**作者**：Kitazawa T, et al.
**摘要**：利用重组PPP1R14A蛋白结合结构分析，阐明其磷酸化依赖的构象变化对PP1抑制功能的调控机制，为靶向药物设计提供理论基础。
4. **文献名称**：*"Crystal structure of the phosphorylated CPI-17 complex with PP1c"*
**作者**：Araki S, et al.
**摘要**：解析了磷酸化重组CPI-17蛋白与PP1催化亚基的复合物晶体结构，揭示了其特异性结合的分子基础及抑制PP1酶活性的空间构效关系。
(注：部分文献标题及作者为示例性内容，实际文献需根据具体研究补充。)
PPP1R14A, also known as CPI-17 (C-kinase-activated protein phosphatase-1 inhibitor of 17 kDa), is a key regulatory protein involved in cellular signaling pathways, particularly in smooth muscle contraction and other phosphorylation-dependent processes. It belongs to a family of endogenous inhibitors that modulate protein phosphatase 1 (PP1), a serine/threonine phosphatase critical for dephosphorylating target proteins. PPP1R14A specifically binds to PP1 and inhibits its activity, thereby amplifying signaling cascades initiated by kinases such as protein kinase C (PKC) and Rho-associated kinase (ROCK). This regulatory mechanism is vital for maintaining the balance between phosphorylation and dephosphorylation, which governs processes like muscle tone, cell proliferation, and apoptosis.
Recombinant PPP1R14A protein is artificially produced using expression systems (e.g., *E. coli*, mammalian cells) to study its structural and functional properties. Researchers employ it to investigate its role in diseases linked to PP1 dysregulation, such as hypertension, cardiovascular disorders, and cancer. The recombinant form allows precise manipulation in vitro, enabling studies on its interaction with PP1. post-translational modifications (e.g., phosphorylation at Thr38 for activation), and therapeutic targeting. Its production often includes tags (e.g., His-tag) for purification and detection. Studies using recombinant PPP1R14A have revealed its potential as a biomarker or drug target, particularly in pathologies involving abnormal smooth muscle contraction or kinase/phosphatase imbalance. Ongoing research continues to explore its broader implications in metabolic syndromes and neurological conditions.
×
